DLL3 and neuroendocrine neoplasm: The data showing that DLL3 is upregulated in high-grade neuroendocrine neoplasms (NENs) and associated with worse clinical outcomes support the potential of DLL3-targeting agents for the treatment of these challenging tumors, and some of these agents have already demonstrated clinical antitumor activity.